Aspire Biopharma Holdings authorized a $10 million common stock repurchase program effective September 9, while changing its name to Aspire-Lakewood Holdings. For investors, the plan creates a potential capital-return route, but purchases are discretionary, have no required share amount, and can be suspended or terminated without notice.

Key Highlights

  • Aspire Biopharma Holdings changed its corporate name to Aspire-Lakewood Holdings effective September 8.
  • The ASBP trading symbol, Nasdaq listing and CUSIP number remain unchanged after the name change.
  • DCSC generated approximately $209.5 million in Revenue and $22.3 million of Adjusted EBITDA for 2025.

Aspire Biopharma Holdings, Inc. authorized a $10 million common stock repurchase program effective September 9, giving the board authority to buy shares through open-market or privately negotiated transactions. The company also changed its name to Aspire-Lakewood Holdings, Inc. while retaining its Nasdaq listing and ASBP trading symbol.

$10 Million Authorization and Name Change

Repurchases may occur at times and in amounts determined by market conditions, regulatory requirements, company performance, price, Capital and Liquidity needs, and other management priorities. The program does not require Aspire-Lakewood Holdings to purchase a specific number of shares and has no expiration date. The board may suspend or end it at any time without prior notice. Stockholders do not need to take action, certificates bearing the former name remain valid, and the CUSIP number is unchanged.

DCSC Metrics Cited Behind the Program

The company said the authorization reflects its confidence in its long-term holding-company strategy and free Cash Flow generation. It also cited Dura Control Systems Corp.’s results, including approximately $209.5 million of revenue and $22.3 million of Adjusted EBITDA for the twelve months ended December 31, 2025. For the six months ended June 30, 2026, DCSC produced approximately $103.9 million of revenue and $10.5 million of Adjusted EBITDA. Aspire reported approximately 1.5 million common shares outstanding as of September 8 and linked 2025 adjusted EBITDA of approximately $22.3 million to approximately $15.00 per share.